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ABSTRACT 
The relationship between physiological and psychological stress and immune function is 
widely recognised; however, there is little evidence to confirm a direct link between 
depressed immune function and incidence of illness in athletes. Purpose: To examine the 
relationship between salivary-Immunoglobulin A (s-IgA) and upper respiratory infections 
(URI) in a cohort of professional athletes over a prolonged period of time. Methods: Thirty-
eight elite America‟s Cup Yacht Racing athletes were studied over 50weeks of training. 
Resting, unstimulated saliva samples were collected weekly (38 h post-exercise, consistent 
time of day, fasted) together with clinically confirmed URI, training load and perceived 
fatigue rating. Results: S-IgA was highly variable within (CV:48%) and between subjects 
(CV:71%). No significant correlation was found between absolute s-IgA concentration and 
the incidence of URI among athletes (r=0.11). However, a significant (28%, P<0.005) 
reduction in s-IgA occurred during the 3weeks prior to URI episodes and returned to baseline 
by 2weeks following URI. When an athlete did not have, or was not recovering from URI, a 
s-IgA value <40% relative to their mean healthy s-IgA concentration indicated a one in two 
chance of contracting an URI within 3weeks. Conclusion: On a group basis, relative s-IgA 
determined a substantial proportion of the variability in weekly URI incidence. The typical 
decline in an individual‟s relative s-IgA over the 3 weeks prior to URI appears to precede and 
contribute to URI risk, with the magnitude of the decrease related to the risk of URI, 
independent of the absolute s-IgA concentration. These findings have important implications 
for athletes and coaches in identifying periods of high URI risk. 
 
Key Words: IMMUNOLOGY, ILLNESS, UNDERLYING FATIGUE, SAILING, 
AMERICA‟S CUP 
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INTRODUCTION 
 
Paragraph 1 Upper respiratory infections (URI) are the most common medical complaint 
of athletes (26, 35) and can negatively affect training and performance (33). For example, 
during a two year training period prior to the 31
st
 America‟s Cup, 40% of all illnesses were 
URI and accounted for 60% of days absent from sailing due to illness (26). In addition, elite 
athletes seem to be more susceptible to URI than recreationally active or sedentary 
individuals (39), with the risk of illness increasing during periods of heavy training and 
competition (21, 30, 32). This increased susceptibility to URI is thought to be largely due to a 
depression of immune system function as a result of multifactorial stress including 
physiological, psychological, environmental and  behavioral (4-6, 42) (see Gleeson (11) for 
review).  
Paragraph 2 Approximately 95% of all infections are initiated at the mucosal surfaces 
(2), which are protected by antimicrobial proteins of which secretory immunoglobulin A 
(IgA) is the most abundant (3). Secretory IgA provides an immunological barrier by 
neutralizing and preventing viral pathogens from penetrating the body through the mucosal 
surfaces (20, 24). In the buccal cavity, the synthesis and secretion of salivary IgA (s-IgA) 
responds almost instantaneously to stress (2), resulting in transitory fluctuations in 
concentration and secretion rate (40).  
Paragraph 3 Elite athletes are frequently exposed to exercise stress, and the effects of 
both acute and chronic exercise on s-IgA have been well documented (14, 21, 23, 30, 42) and 
appear to depend on the fitness level of the individual as well as the training load. In elite 
athletes, s-IgA concentration and secretion rate decrease after a bout of strenuous exercise, of 
either high volume (29) or maximal intensity (9), or during prolonged periods involving 
repeated bouts of strenuous training  (21). Much of the immunology research in athletes has 
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concentrated on post-exercise salivary immunity when athletes seem to experience a 
transitory decrease in s-IgA for up to 24 h post strenuous training or competition. It is during 
this “open window” period of immune depression (31) when athletes are thought to be at 
greatest risk of URI. However, there are few longitudinal studies that have examined the 
relationship between immune depression and the incidence of URI (8, 15, 22, 30) and these 
typically have had a low number of subjects or low sample collection frequency. 
Nevertheless, an absolute s-IgA concentration of less than 40 mg·L
-1
 (15) and an absolute s-
IgA secretion rate of less than 40 µg·min
-1
 (8) have been reported to be associated with 
increased incidence of URI in athletes.  
Paragraph 4 Large within and between subject variations in s-IgA concentration have 
been reported in elite rowers and swimmers, recreationally active and sedentary individuals 
(10, 25). This variation implies that the secretion of s-IgA may be specific to the individual 
and their recent environmental circumstances, and advocates regular monitoring of well 
controlled basal values to determine individual reference data. These variations also question 
the validity of studies which have few sample measures (13). Furthermore, consensus 
regarding the control of factors known to affect basal s-IgA has yet to be determined, such as: 
the residual effects of exercise, nutrition status (fasted vs non fasted), circadian rhythms and 
caffeine ingestion (see Gleeson et al. (16) for review). These inconsistencies in methodology 
have led to inconsistancies in the literature and make it difficult to compare studies (38). 
Furthermore, in determining URI, the majority of studies have used self-reporting illness logs 
that have not been validated against objective criteria (39) and may be prone to inconsistency 
and over-reporting (16). Few studies have used clinical diagnosis to confirm the presence of 
URI.  
Paragraph 6 The overall aim of this study was to examine the relationship between s-IgA 
and URI in a relatively large cohort of athletes over a prolonged period of time (weekly 
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samples for 50 weeks). The specific objectives were: to document the within and between 
athlete variability in resting s-IgA; examine the relationship between s-IgA and URI, and 
whether s-IgA values indicated the presence or imminent onset of URI; and to investigate the 
relationships of subjective fatigue rating and physical stress (sailing and training load) with s-
IgA. 
 
 
METHODS 
 
Paragraph 7 Subjects. Thirty eight elite America‟s Cup Yacht Racing athletes (mean ± 
SD: age 36 ± 7 years, body mass 92 ± 12 kg, body fat 14 ± 4 % and arm ergometer VO2max 
50 ± 5 ml·min
-1
·kg
-1
) were studied over 50 weeks of sailing and training. The subjects were 
all professional athletes contracted to one of the top four America‟s Cup teams, with their 
collective experience and success including: 20 Olympic Games representations, 8 Olympic 
medals, 90 World Championship titles and more than 100 America‟s Cup campaigns.  
Paragraph 8 Experimental design. A prospective longitudinal study design was used to 
collect saliva samples, illness reports, training load and fatigue ratings over an 18-month 
sailing and training preparation period prior to the 32
nd
 America‟s Cup held in Valencia, 
Spain in 2007. Informed consent was obtained from all athletes and the study was conducted 
within the team‟s normal training and competition schedule and overseen by the team‟s 
sports science and medical support staff. The study was approved by the Loughborough 
University Ethical Advisory Committee.  
Paragraph 9 America’s Cup Yacht Racing. The America‟s Cup is the oldest trophy in 
modern day sports, dating back to 1851. It is regarded as the pinnacle of yacht racing and is 
held every three to four years. The 24-ton high performance racing yachts are sailed by 17 
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athletes around a specific race course. Races are 1.5 to 2.5 h in duration and all maneuvers 
on-board are performed manually without assistance from stored energy. The physiological 
demands are specific to the role of the athlete and largely dependent on the weather 
conditions. The crew can be divided into two groups based on the physical demands of each 
position, with grinders, mastmen, bowmen and pitmen in high physically demanding roles, 
and helmsmen, navigators, trimmers, tacticians and strategists in moderately demanding 
roles.  
Paragraph 10 Work load. The athletes‟ week typically consisted of 6 training days and 
one day of rest. Their working day was typically between 8 and 14 h in duration, beginning at 
08:00 h with approximately 1 h of land-based strength and conditioning exercise („training‟) 
followed by meetings and preparing the boats for sailing. The volume of sailing varied 
between 3 to 7 h per day whereafter, 1 to 3 h of boat maintenance was carried out. This was 
followed by further meetings and on some occasions an additional short bout of strength and 
conditioning exercise. 
Paragraph 11 Sailing and Training data. In order to calculate an index of overall 
sailing and training load, the product of volume and intensity was ranked on a scale of 1 to 5 
(1 = very low load; 5 = very high load) for sailing and training separately. These were 
combined for the cohort with a weighting of 2/3 for sailing and 1/3 for training to provide an 
index of combined sailing and training load.  
Paragraph 12 Saliva collection. Saliva samples were collected weekly at 07:45 h in a 
fasted state, the day after a rest or no training day ensuring a minimum of 38 h rest after the 
previous training session. Whole mixed saliva samples were collected prior to training and 
breakfast or coffee (1) 5 min after consuming 250 ml of water. Athletes sat quietly with their 
head tilted forward and passively dribbled (with minimal orofacial movement) approximately 
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1 ml of unstimulated saliva into a pre-marked specimen container. Samples were placed in a 
pre-cooled insulated container and taken directly to the laboratory for analysis.  
Paragraph 13 Saliva analysis. Saliva samples were analysed for s-IgA concentration 
within 2 h of collection. Salivary IgA concentration was determined by means of 
immunonephelometry using a BN ProSpec analyser (Dade-Behring Marburg GmbH, 
Marburg, Germany). In summary, IgA in human saliva forms immune complexes in an 
immunochemical reaction with specific antibodies. These complexes scatter a beam of light 
passed through the sample. The intensity of the scattered light is proportional to the 
concentration of IgA in the sample. The result is evaluated by comparison with a standard of 
known concentration. The reagents used were N Antiserum to Human IgA (Dade Behring 
Marburg GmbH, Marburg, Germany), produced by immunization of rabbits with highly 
purified human immunoglobulin A with Sodium azide (< 1 g.L
-1
) added as a preservative and 
N Diluent (Dade Behring Marburg GmbH, Marburg, Germany), which contains Phosphate 
buffered saline and sodium azide (< 1 g.L
-1
) as a preservative. Samples were assayed in 
duplicate after being brought to room temperature and spun at 14,000 rpm for 6 minutes. 
Supernatant was recovered and transferred to a sample cup. After a 1:5 dilution with N-
Diluent, sample and antiserum were incubated for 6 minutes prior to immunocomplexes 
measurement using a 380 nm light beam. The within-run coefficients of variation (CV) for 
each assay were on average 1.6% and the mean between-run CV was 3.7% with a total CV of 
4%. The limit of sensitivity was 14 mg·L
-1
. Contaminated samples or those containing 
sputum were excluded from analysis.  
Paragraph 14 Illness reports. Respiratory illness and infections were recorded by the 
team‟s Physician, who was present during all data collection and team training sessions. An 
URI was only recorded if the athlete required medication (either systemic or antibiotic) and 
missed at least one sailing or training session as a result of the illness (26). Medical 
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consultations, allergies and the prescription of vitamin supplementation or prophylactic 
treatment were not considered an URI episode. A recurring illness was defined as “any URI 
occurring within one week of a previously recorded episode” and excluded from analysis.  
Paragraph 15 Fatigue rating. A simple three scale subjective fatigue rating 
questionnaire was completed at the same time as saliva collection during the last 30 weeks of 
the study period. The questionnaire asked: “How rested do you feel?” to which there were 
three answers: “worse than normal”, “normal” or “better than normal”.  
Paragraph 16  Statistical analysis. Data are expressed as mean ± SEM, and the level of 
significance was set at P < 0.05. The reliability of s-IgA was calculated within and between 
subjects with the coefficient of variation (CV). Independent samples t test was used to 
identify differences between athletes in high and moderate physically demanding roles. 
Pearson‟s product moment correlations were used to determine the strength of relationships. 
Paragraph 17 The mean s-IgA concentration for each individual was calculated as the 
mean of all No URI values (i.e. s-IgA values were excluded from the mean when a URI 
episode was present), and individual relative s-IgA was calculated as percentage of this mean 
value. Paired samples t test was used to assess any differences between s-IgA during URI and 
No URI. Relative s-IgA concentrations before, during and after URI were compared with 
repeated measures ANOVA and a Bonferroni post-hoc test to analyse where any differences 
lay. These procedures were also used to compare s-IgA for different ratings of fatigue. 
Analyses were performed using SPSS version 14.0 for Windows.  
Paragraph 18 The incidence of low s-IgA values (< 40% and < 70% of an individual‟s 
mean) was calculated in the weeks before, during and after URI. The probability of low s-IgA 
leading to URI within 3 weeks (Predictability of URI), when URI was not present or recent 
(i.e. excluding during URI or 1-week post-URI) was calculated as the number of samples 
during pre-URI as a percentage of pre- and No URI. 
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RESULTS 
 
Paragraph 19 Over the 50-week study period 1,424 saliva samples were analysed, with a 
mean s-IgA concentration of 136 ± 3 mg·L
-1
. Salivary IgA concentration was highly variable 
within-subjects, with a mean coefficient of variation (CV) of 48%. The difference in the 
mean value between the lowest and the highest individual was almost 10 fold (35 ± 4 mg·L
-1
 
vs. 314 ± 27 mg·L
-1
; Figure 1A) and the between-subjects CV was 71%. The s-IgA 
concentration of athletes with sailing roles of moderate and high physical demands were 
similar (moderate: 149 ± 20 mg·L
-1
; high: 127 ± 12 mg·L
-1
).  
Paragraph 20 A total of 102 incidents of URI were recorded, resulting in 129 weeks of 
infection with symptoms ranging from 1 to 3 weeks in duration. The incidence of URI was on 
average 2.7 ± 0.3 infections per athlete over the 50-week period (Figure 1B), and was similar 
for athletes in roles with moderate (2.9 ± 0.5) and high (2.5 ± 0.4) physical demands.  
Paragraph 21 There was no relationship between an athlete‟s mean s-IgA and his 
number of URI (r = 0.11). When s-IgA values were normalised to each individual‟s mean, 
relative s-IgA concentration was 28% lower during URI than when there was no URI (P < 
0.005; Figure 2). For the cohort, the number of URI in each week was inversely related to the 
mean weekly relative s-IgA concentration (Figure 3). The four lowest weekly mean relative 
s-IgA values (< 70%) were recorded during the pre-season training period (March and April) 
and three of these weeks were coincident with the highest incidence of URI. Relative s-IgA 
declined progressively during the 3 weeks prior to URI, being significantly lower during URI 
in comparison to 4 weeks prior, before returning to above baseline by 2 weeks following URI 
(Figure 4).  
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Paragraph 22 The frequency of low s-IgA values (< 40% of an individual‟s mean 
healthy value) was higher in the weeks prior to, during and immediately after URI, than when 
no URI was present or imminent, being almost 6-fold greater in the week before infection 
(Table 1). When an individual did not have an URI or was not recovering from an URI, a low 
relative s-IgA value (< 40%) suggested a 48% chance (23/48) of contracting an URI within 3 
weeks, compared with a 28% chance (74/263) of URI for relative s-IgA values of less than 
70%. However, during the 3 weeks prior to URI, 89% and 65% of s-IgA values were greater 
than 40% and 70% of relative s-IgA, respectively. 
Paragraph 23 The mean total sailing and training exposure for each athlete over the 50 
weeks was 986 h, (749 h sailing; 237 h training) and the mean weekly combined sailing and 
training load ranged from 2.0 to 4.4. No relationship was found between weekly combined 
sailing and training load and URI (r = 0.002). However, a significant correlation was found 
between the weekly sailing and training load and the weekly percentage of relative mean s-
IgA concentration (r = 0.41, Figure 5). 
Paragraph 24 There was a difference between the athletes‟ relative s-IgA concentration 
according to their fatigue rating, with s-IgA being significantly different for each of the 
fatigue ratings: “better than normal” 131 ± 8%; “normal” 103 ± 4%; “worse than normal” 69 
± 5% (P < 0.005, Figure 6).  
 
 
DISCUSSION                          
 
Paragraph 25 This is the largest salivary immunology study on elite athletes to date. The 
main findings suggest that the relative s-IgA concentration is associated with, and can help to 
predict URI in elite athletes. For the cohort, relative s-IgA determined a substantial 
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proportion of the variability of URI incidence. The typical decline in an individual‟s relative 
s-IgA over the 3 weeks before URI appears to pre-empt and contribute to URI risk, with the 
level of risk related to the extent of the decline in s-IgA, independent of the absolute 
concentration. In addition, the s-IgA of elite athletes is highly variable, both within and 
between subjects, and is related to the athlete‟s perception of underlying fatigue. These 
results suggest that regular monitoring of resting s-IgA may benefit athletes and coaches in 
determining the risk of URI and fatigue in elite athletes. 
Paragraph 26 The mean s-IgA concentration in the current study is similar to that 
reported by several previous studies in exercise immunology (17, 37, 41). However, the 
differences between studies are extensive, with some studies having a 15-fold greater (28) 
mean s-IgA concentration than others (23). These differences could be attributed to variations 
in: methodology, assay assessment techniques, control for basal resting values, different 
cohorts of subjects and large between-subject variability. It is therefore difficult to make 
comparisons between studies (38), particularly with respect to absolute values of s-IgA.  
Paragraph 27 The volume of sailing per week was greater (almost 30%) than that 
reported during the 31
st
 America‟s Cup (26), as was the ratio of sailing to training volume 
(26). This was possibly due to the more favourable sailing conditions at the venue of the 32
nd
 
America‟s Cup.  The correlation between the combined sailing and training load and the 
athletes‟ weekly s-IgA was in accordance with previous reports (8, 21, 28-30, 42). 
Paragraph 28 The incidence of URI (2.7 episodes per 1,000 h sailing and training) was 
similar to that previously reported in America‟s Cup yacht racing (26), with a similar 
incidence for athletes in sailing roles with high and moderate physical demands.  
Paragraph 29 The large within-subject variation in the current study (CV: 48%) concurs 
with results found in elite level rowing (25) and swimming (10). Elite athletes have been 
reported to have greater within-subject variability than recreationally active or sedentary 
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individuals (10), which may be due to the many stressors encountered as a result of high 
training loads and competition. These variations may be characteristic of the individual and 
their response to recent circumstances, and may indicate that some athletes are more 
susceptible (or adaptable) to stress than others. This variation was despite carefully 
controlling for a range of factors known to influence s-IgA. In fact, the methodological care 
with which samples were collected in standardised conditions (after a rest day, at a consistent 
time of day, in a fasted state and without caffeine ingestion) was one of the strengths of the 
current study. Many studies have not controlled for factors known to influence the 
concentration of s-IgA such as: the residual effects of exercise (10), large data collection 
windows (10, 36) and caffeine ingestion (15, 30). Other factors known to influence s-IgA 
which have not been controlled for in the literature include: time of day and circadian rhythm 
effects (6) and nutritional status (12). Whilst many of these inconsistencies may explain some 
of the discrepancies found in the literature, even when well controlled for in this study, there 
was still a large within-subject variability, which highlights the complex nature of the 
mucosal immune system. Saliva samples were collected 38 h post-exercise to ensure that the 
athletes were well rested and exclude any residual effects of exercise; hence, these results are 
related to the resting status of the individual and should not be compared with the effects of 
acute stress or temporal changes in s-IgA.  
Paragraph 30 Another factor affecting baseline values is sample size (18). The current 
study collected up to 50 samples for each athlete, which is considerably more than the range 
of 2 to 13 samples in most previous longitudinal studies (8, 10, 13-15, 19, 21-23, 34, 41). 
With s-IgA being highly variable, the smaller the number of samples, the less likelihood of 
detecting a real change (18), which could account for some of the inconsistencies in the 
literature. In addition, a low N means that any outlier values may have a large influence on 
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the correlation coefficient, thereby increasing the risk or chance effect of a significant 
correlation.  
Paragraph 31 The large between-subjects variability in s-IgA concentration found in this 
study (CV: 71%) concurs with previous reports (10, 25) and strongly indicates that resting 
values of s-IgA are specific to the individual. Hence, it is the aetiology of this variability 
which may provide important answers to athletes‟ susceptibility to illness.  
Paragraph 32 No association was found between the absolute mean s-IgA concentration 
of each athlete and the incidence of URI, indicating that athletes with low s-IgA 
concentration were no more at risk of URI than athletes with high values. This is contrary to 
previous reports, which have suggested that an absolute concentration of < 40 mg·L
-1 
(15) or 
an absolute rate of secretion of < 40 µg·min
-1
 (8) may increase the risk of URI. Based on 
these previous reports, the athlete with the lowest mean s-IgA concentration (35 ± 4 mg·L
-1
) 
in the current study would be at chronic risk of infection, when in fact this athlete reported no 
incidence of illness during the study, and coincidently, the athlete with the highest mean 
value (314 ± 27 mg·L
-1
) reported the greatest number of URI (8). Based on these data, 
relative values are the preferable means of expressing resting s-IgA and provided sufficient 
resting samples are measured, will provide a valid baseline for each individual.  
Paragraph 33 A main finding of this study was the association between s-IgA and URI, 
where the weekly mean relative s-IgA concentration was negatively related to the incidence 
of URI (r = -0.54, P < 0.005). This indicates that on a group basis the weekly mean s-IgA 
determines a substantial proportion (29%) of the variation in URI incidence. Hence, 
monitoring group s-IgA may assist coaching staff in identifying periods of high risk in order 
to apply appropriate intervention (see Pyne et al. (34) for a review of intervention strategies). 
Previously, the relationship between s-IgA and URI in athletes has been less than convincing, 
with only a few studies having suggested an association (8, 13, 15, 22). These results are 
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therefore important in confirming that s-IgA plays an important role in the incidence of URI 
and that the changes in s-IgA within an individual may be directly responsible for URI risk or 
may be a surrogate measure for some other immune system function. Interestingly, the lowest 
weekly s-IgA values for the group occurred during the first 6 weeks of training after a 2-
month winter off-season period, and coincided with the highest weekly incidence of URI. 
This is likely to be a combined result of: changes in environment, increased sailing and 
training load, changes in diet, psychological stress associated with returning to the 
competitive team environment and exposure to pathogens during public travel on return to 
the team (34). 
Paragraph 34 On an individual basis there was also a difference in s-IgA concentration 
(~30%) between when an athlete had URI and when No URI was present. When the time 
course of s-IgA was examined in the weeks before, during and after an URI episode, there 
was a progressive decline in the 3-weeks prior to URI and a subsequent return to baseline 
within 2-weeks following URI. The cause and effect relationship as inferred by Mackinnon et 
al. (22), where the decrease in s-IgA prior to infection could be the result of the incubation 
period prior to expression of URI symptoms, is unlikely to apply to the findings of the 
present study, as the incubation period of URI is usually only 1 to 3 days (7). Therefore, it is 
postulated that the reduction in s-IgA in the weeks prior to URI is a contributing factor to the 
subsequent incidence of URI. It seems that on average, a 30% reduction in relative s-IgA 
from healthy values may increase the risk of URI, which is further supported by the increased 
frequency (2.5-fold) of s-IgA values less than 70% of an individual‟s mean healthy value 
during the week prior to URI when compared with times when no infection was present. The 
results further suggest that the greater the drop below an individual‟s mean healthy s-IgA 
concentration, the greater the risk of URI.  
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Paragraph 35 An important finding of this study was that for individual athletes low 
relative s-IgA concentrations were associated with an increased risk of URI. For example: 
when an athlete was healthy (did not have URI or was not recovering from URI), a low s-IgA 
value (< 40% of an individual‟s mean healthy value) suggested a 48% chance of contracting 
an URI within 3 weeks, compared with a 28% chance when values were below 70% of an 
individual‟s healthy mean s-IgA concentration. Therefore, the lower the s-IgA value below 
baseline, the greater the probability of contracting an URI.  Although it should be noted that 
38% of URI were not preceded by values below baseline and only 11% of URI were 
preceded by values < 40%. Hence, the absence of low s-IgA values was no guarantee of 
remaining healthy, indicating the multifactorial nature of immunity, and that factors other 
than reduced s-IgA alone contribute to the risk of infection.   
Paragraph 36 No significant relationship was found between sailing and training load 
and the incidence of URI, which is contrary to previous reports in a number of different 
sports, including: elite level swimming (39), elite tennis (30) and endurance running (27, 32).  
This may be due to the difficulty in accurately determining the total work load that each 
individual is exposed to, as athletes are often required to perform large volumes of work over 
and above the physical requirements of sailing and training, including: boat maintenance, sail 
packing, boat sanding, as well as the psychological stress of design and performance 
meetings . 
Paragraph 37 As fatigue is common in athletes during periods of heavy training and 
competition, the relationship between salivary immunity and recovery is of great interest. To 
our knowledge, this is the first report of subjective fatigue being associated with relative s-
IgA concentration. The results suggest that a simple fatigue rating reflects immune status to 
some extent, and appears to validate the use of a simple subjective questionnaire in 
monitoring underlying fatigue and recovery of athletes. These findings also imply that an 
S-IgA and Risk of URI in Athletes 
                                                                                  Page | 15                                                                
 
athlete‟s underlying fatigue or psychological state may have a major influence on s-IgA in 
addition to the combined sailing and training load. 
Paragraph 38 In summary, the results of this study confirm the role of s-IgA in the 
incidence of URI in elite athletes. The weekly mean relative s-IgA concentration for the 
cohort was negatively related to the incidence of URI, indicating that on a group basis the 
weekly mean s-IgA determines a substantial proportion of the variation in URI incidence. No 
association was found between the absolute mean s-IgA concentration of each athlete and the 
incidence of URI, indicating that athletes with low mean s-IgA concentration were at no 
greater risk of infection. Consequently, relative values are the preferred means of expressing 
basal s-IgA concentration. The large within and between subjects variability strongly 
indicates that basal values of s-IgA are specific to the individual and a relatively large 
number of samples are required to determine baseline values. Elucidating the aetiology of this 
variability would enhance our understanding of athletes‟ susceptibility to illness.  The 
reduction in s-IgA in the weeks prior to URI appears to be a contributing factor to the 
subsequent incidence of URI, with the magnitude of the decrease related to the risk of URI. 
Furthermore, a simple fatigue rating appears to reflect changes in salivary immunity. The 
results presented in this study advocate frequent monitoring of well controlled resting s-IgA 
in elite athletes. If the results are rapidly available, they may assist athletes and their support 
staff in identifying periods of high URI risk so that appropriate preventative strategies can be 
applied. Furthermore, the use of a simple fatigue questionnaire can provide coaches with 
valuable information on the underlying fatigue status of the athlete. 
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FIGURE LEGENDS 
 
 
FIGURE 1 - Saliva IgA concentration (A, mean ± range) and the number of Upper 
Respiratory Infections (B) for each athlete over the 50 weeks 
 
FIGURE 2 - Saliva IgA concentration during URI (72 ± 5 %) and No URI (100 ± 0 %).  
Data are mean ± SEM of 31 athletes that reported an infection, with each individual‟s relative 
S-IgA values averaged for URI or not. * P < 0.005. 
 
FIGURE 3 - Scatter plot of the weekly number of URI within the subject cohort and Salivary 
IgA (mean of relative values for each individual) (r = 0.54, r
2
 = 0.29, N = 50, P < 0.005). 
 
FIGURE 4 - Salivary IgA concentration for each week Pre, during and Post all infections (N 
= 102). Data are mean ± SEM of individual relative S-IgA (percentage of No URI mean 
values).  * URI significantly different to -4weeks, +1week, +2weeks, P < 0.005;  ** -1week 
significantly different to +2weeks, P < 0.005.  
 
FIGURE 5 - Scatter plot of the weekly Salivary IgA, mean relative values, and the combined 
Sailing and Training load (r = 0.41, r
2
 = 0.17, N = 50, P < 0.005). 
 
FIGURE 6 - Salivary IgA concentration for different fatigue ratings. Data are Mean ± SEM 
of 38 athletes, with each individual‟s relative S-IgA values averaged for each rating. * S-IgA 
for each rating significantly different to the other two (N = 38, P < 0.005). 
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TABLES 
 
TABLE 1. Number and incidence of low relative salivary IgA values (< 70% and < 40% of an individual’s healthy average) 
before, during and after URI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Total number of                                     
s-IgA samples 
Number (% incidence)                                  
of s-IgA <70%  
Number (% incidence)                         
of s-IgA <40%  
No URI  1020   189  ( 18.5 )    25  ( 2.5 ) 
3weeks pre-URI      56     12  ( 21.4 )      3  ( 5.4 ) 
2weeks pre-URI      71     25  ( 35.2 )      8  ( 11.3 ) 
1week pre-URI      83     37  ( 44.6 )    12  ( 14.5 ) 
During URI    109     52  ( 47.7 )    15  ( 13.8 ) 
1week post-URI      85     21  ( 24.7 )    10  ( 11.8 ) 
Predictability of URI 
*
 (%)      28    48 
*
The Predictability of URI was calculated as the percentage of values below each threshold that led to URI 
within 3 weeks, when URI was not present or recent (i.e.: excluding during URI and 1 week post-URI). 
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Figure 1: Saliva IgA concentration (A, mean ± range) and the number of Upper Respiratory 
Infections (B) for each athlete over the 50 weeks  
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Figure 2: Saliva IgA concentration during URI (72 ± 5 %) and No URI (100 ± 0 %).  
Data are mean ± SEM of 31 athletes that reported an infection, with each individual‟s 
relative S-IgA values averaged for URI or not. * P < 0.005. 
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Figure 3: Scatter plot of the weekly number of URI within the subject cohort and 
Salivary IgA (mean of relative values for each individual) (r = 0.54, r
2
 = 0.29, N = 50, 
P < 0.005). 
S-IgA and Risk of URI in Athletes 
                                                                                  Page | 27                                                                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Salivary IgA concentration for each week Pre, during and Post all infections (N = 
102). Data are mean ± SEM of individual relative S-IgA (percentage of No URI mean values).  
* URI significantly different to -4wks, +1wk, +2wks, P < 0.005;  ** -1wk significantly different 
to +2wks, P < 0.005.  
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Figure 5: Scatter plot of the weekly Salivary IgA, mean relative values, and the 
combined Sailing and Training load (r = 0.41, r
2
 = 0.17, N = 50, P < 0.005). 
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Figure 6: Salivary IgA concentration for different fatigue ratings. Data are Mean ± 
SEM of 38 athletes, with each individual‟s relative S-IgA values averaged for each 
rating. * S-IgA for each rating significantly different to the other two (N = 38, P < 
0.005). 
